Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells

Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center), Steven L. Reiner(Columbia University Irving Medical Center), Naofumi Takemoto(The Wistar Institute), John K. Northrop(University of Pennsylvania), Arnob Banerjee(Johnson & Johnson (United States)), E. John Wherry(Parker Institute for Cancer Immunotherapy), Charlly Kao(The Wistar Institute), Hao Shen(Shanghai University of Electric Power), Felix Schambach(The Wistar Institute)
The Journal of Experimental Medicine
August 13, 2007
10.1084/jem.20070841
Cited by 284

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
|Science|2021|932
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873